Interleukins (ILS), a fascinating family of cytokines. Part I: ILS from IL-1 to IL-19

Theoretical Biology Forum

Volumn 107, Issue 1-2, 2014, Pages 13-45

  Fietta, Pieranna ^a   Costa, Elvira ^b   Delsante, Giovanni ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b PEDY   (Greece)

Author keywords

Chemokines; Colony stimulating factors; Cytokines; Growth factors; Hematopoietins; Interferons; Interleukins; Lymphokines; Monokines; Tumor necrosis factors

Indexed keywords

AUTACOID; INTERLEUKIN DERIVATIVE;

ANIMAL; CLASSIFICATION; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKINS; SIGNAL TRANSDUCTION;

EID: 84929506970     PISSN: 00356050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (125)

1. Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007; 37: S34-S45.
2. Kelso A. Cytokines and their receptors: an overview. Ther Drug Monit. 2000; 22: 40-43.
3. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem. 2002; 277: 29355-29358.
4. Dinarello CA. Membrane interleukin-18 revisits membrane IL-1· in T-helper type 1 responses. Eur J Immunol. 2012; 42: 1385-1387.
5. Darnell JE. STATs and gene regulation. Science. 1997; 277: 1630-1635.
6. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998; 67: 481-507.
7. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999; 13: 2905-2927.
8. Heaney ML, Golde DW. Soluble receptors in human disease. J Leukoc Biol. 1998; 64: 135-146.
9. Hilton DJ. Negative regulators of cytokine signal transduction. Cell Mol Life Sci. 1999; 55: 1568-1577.
10. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001; 19: 378-387.
11. Huising MO, Kruiswijk CP, Flik G. Phylogeny and evolution of class-I helical cytokines. J Endocrinol. 2006; 189: 1-25.
12. Chavez LL, Gosavi S, Jennings PA, Onuchic JN. Multiple routes lead to the native state in the energy landscape of the ‚-trefoil family. Proc Natl Acad Sci USA. 2006; 103: 10254-10258.
13. Huang N, Chen H, Sun Z. CTKPred: an SVM-based method for the prediction and classifica- tion of the cytokine superfamily. Protein Eng Des Sel. 2005; 18: 365-368.
14. Steinke JW, Borish L. Cytokines and chemokines. J Allergy Clin Immunol. 2006; 117: S441-S445.
15. Aarden LA, Brunner TK, Cerottini JC, Dayer JM. Revised nomenclature for antigen-non- specific T cell proliferation and helper factors. J Immunol. 1979; 123: 2928-2929.
16. Liles WC, Van Voorhis WC. Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis. 1995; 172: 1573-1580.
17. WHO-IUIS Nomenclature Subcommittee on Interleukin Designation. Nomenclature for secreted regulatory proteins of the immune system (interleukins). Bull World Health Organ. 1991; 69: 483-486.
18. IUIS/WHO Nomenclature Committee. Nomenclature for secreted regulatory proteins of the immune system (interleukins): update. Bull World Health Organ. 1994; 72: 811-812.
19. IUIS/WHO Standing Committee on Interleukin Designation. Nomenclature for secreted regulatory proteins of the immune system (interleukins): update. Bull World Health Organ. 1997; 75: 175.
20. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013; 39: 1003-1018.
21. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011; 23: 598-604.
22. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995: 86: 1243-1254.
23. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Ann Rev Immunol. 2011; 29: 71-109.
24. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012; 13: 722-728.
25. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011; 23: 613-619.
26. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007; 89: 729-734.
27. Remick DG. Interleukin-8. Crit Care Med. 2005; 33: S466-S467.
28. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000; 67: 757-766.
29. Fietta P, Delsante G. The effector T helper cell triade. Riv Biol. 2009; 102: 61-74.
30. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007; 25: 821-852.
31. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci. 2012; 1247: 56-68.
32. O’Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004; 10: 801-805.
33. Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol. 2013; 4: 315.
34. Dinarello CA. IL-1: Discoveries, controversies and future directions. Eur J Immunol. 2010; 40: 599-606.
35. Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O’Neill L et alii. IL-1 family nomenclature. Nat Immunol. 2011; 11: 973.
36. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Semin Immunol. 2013; 25: 394-407.
37. Garlanda C, Riva F, Bonavita E, Gentile S, Mantovani A. Decoys and regulatory "receptors" of the IL-1/Toll-like receptor superfamily. Front Immunol. 2013; 4: 180.
38. Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011; 118: 5813-5823.
39. Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol. 2013; 25: 389-393.
40. Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH et al. The interleukin-1· precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol. 2013; 4: 391.
41. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I et al. IL-1 acts directly on CD4+ T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA. 2009; 106: 7119-7124.
42. Ben-Sasson SZ, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med. 2013; 210: 491-502.
43. Lie PP, Cheng CY, Mruk DD. The biology of interleukin-1: emerging concepts in the regulation of the actin cytoskeleton and cell junction dynamics. Cell Mol Life Sci. 2012; 69: 487-500.
44. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008; 26: 453-479.
45. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol. 2012; 13: 1187-1195.
46. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013; 38: 13-25.
47. Lan RY, Selmi C, Gershwin ME. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun. 2008; 31: 7-12.
48. Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol. 2003; 112: 653-665.
49. Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, Bonder CS et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev. 2012; 250: 277-302.
50. Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan RC et al. Role for inter-leukin-3 in mast-cell and basophil development and in immunity to parasites. Nature. 1998; 392: 90-93.
51. Ebner S, Hofer S, Nguyen VA, Furhapter C, Herold M, Fritsch P et al. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into DCs that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. J Immunol. 2002; 168: 6199-6207.
52. Hong H, Shi Z, Qiao P, Li H, McCoy EM, Mao P et al. Interleukin-3 plays dual roles in osteoclastogenesis by promoting the development of osteoclast progenitors but inhibiting the osteoclastogenic process. Biochem Biophys Res Commun. 2013; 440: 545-550.
53. Asquith KL, Ramshaw HS, Hansbro PM, Beagley KW, Lopez AF, Foster PS. The IL-3/ IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol. 2008; 180: 1199-1206.
54. Dentelli P, Rosso A, Olgasi C, Camussi G, Brizzi MF. IL-3 is a novel target to interfere with tumor vasculature. Oncogene. 2011; 30: 4930-4940.
55. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999; 17: 701-738.
56. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000; 105: 1063-1070.
57. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003; 300: 1527-1528.
58. Bhattacharjee A, Shukla M, Yakubenko VP, Mulya A, Kundu S, Cathcart MK. IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic Biol Med. 2013; 54: 1-16.
59. Fallon PG, Jolin HE, Smith P, Emson CL, Townsend MJ, Fallon R et al. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity. 2002; 17: 7-17.
60. Oliver JA, Stolberg VR, Chensue SW, King PD. IL-4 acts as a potent stimulator of IFN-Á expression in CD8+ T cells through STAT6-dependent and independent induction of Eomesodermin and T-bet. Cytokine. 2012; 57: 191-199.
61. Cooney LA, Towery K, Endres J, Fox DA. Sensitivity and resistance to regulation by IL-4 during Th17 maturation. J Immunol. 2011; 187: 4440-4450.
62. Lazarski CA, Ford J, Katzman SD, Rosenberg AF, Fowell DJ. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PloS One 2013; 8: e71949.
63. Takatsu K. Interleukin- and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87: 463-485.
64. Takatsu K, Kouro T, Nagai Y. Interleukin 5 in the link between the innate and acquired immune response. Adv Immunol. 2009; 101: 191-236.
65. Horikawa K, Takatsu K. Interleukin-5 regulates genes involved in B cell terminal maturation. Immunology. 2006; 118: 497-508.
66. Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol. 2008; 20: 288-294.
67. May LT, Ghrayeb J, Santhanam U, Tatter SB, Sthoeger Z, Helfgott DC et al. Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem. 1988; 263: 7760-7766.
68. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014; 2: 288-294.
69. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80: 227-236.
70. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities. Int J Biol Sci. 2012; 8: 1237-1247.
71. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374: 1-20.
72. Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger DA, Chen J. Interleukin-7 receptor signaling network: an integrated system perspective. Cell Mol Immunol. 2008; 5: 79-89.
73. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, Durum SK. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 2005; 16: 513-533.
74. Ceredig R, Rolink AG. The key role of IL-7 in lymphopoiesis. Semin Immunol. 2012; 24: 159-164.
75. Badot V, Durez P, Van den Eynde BJ, Nzeusseu-Toukap A, Houssiau FA, Lauwerys BR. Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines. J Cell Mol Med. 2011; 15: 2335-2342.
76. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol. 2006; 24: 657-679.
77. Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naïve cells into memory-phenotype cells. Nat Immunol. 2011; 12: 478-484.
78. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002; 99: 3892-3904.
79. Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med. 2009; 266: 141-153.
80. Zeilhofer HU, Schorr W. Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol. 2000; 7: 178-182.
81. Stillie R, Farooq SM, Gordon JR, Stadnyk AW. The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol. 2009; 86: 529-543.
82. Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA. Interleukin 8 and cardiovascular disease. Cardiovasc Res. 2009; 84: 353-360.
83. Sabatino G, Nicoletti M, Neri G, Saggini A, Rosati M, Conti F et al. Impact of IL -9 and IL-33 in mast cells. J Biol Regul Homeost Agents. 2012; 26: 577-586.
84. Knoops L, Renauld JC. IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors. 2004; 22: 207-215.
85. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011; 186: 3283-3288.
86. Lu Y, Hong S, Li H, Park J, Hong B, Wang L et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 2012; 122: 4160-4171.
87. Mosser DM, Zhang X. Interleukin-10: new perspective on an old cytokine. Immunol Rev. 2008; 226: 205-218.
88. Langer JA, Cutrone EC, Kotenko S. The class II cytokine receptors (CFR2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev. 2004; 15: 33-48.
89. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the inter-leukin-10 receptor. Annu Rev Immunol. 2001; 19: 683-765.
90. King A, Balaji, Le LD, Combleholme TM, Keswani SG. Regenerative wound healing: the role of interleukin-10. Adv Wound Care (New Rochelle). 2014; 3: 315-323.
91. Garbers C, Scheller J. Interleukin-6 and interleukin-11: same same but different. Biol Chem. 2013; 394: 1145-1161.
92. Zhang J, Zhang Y, Dutta DJ, Argaw AT, Bonnamain V, Seto J et al. Proapoptotic and antiapoptotic actions of Stat1 versus Stat3 underlie neuroprotective and immunoregulatory functions of IL-11. J Immunol. 2011; 187: 1129-1141.
93. Putoczki T, Ernst M. More that a siderkick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol. 2010; 88: 1109-1117.
94. Bozza M, Bliss JL, Dorner AJ, Trepicchio WL. Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells. J. Interferon Cytokine Res. 2001; 21: 21-30.
95. Matsumoto T, Kuriwaka-Kido R, Kondo T, Endo I, Kido S. Regulation of osteoblast differentiation by interleukin-11 via AP-1 and Smad signaling. Endocr J. 2012; 59: 91-101.
96. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003; 19: 641-644.
97. Jones LL, Vignali DA. Molecular interactions within the IL-6/IL-12 cytokine/receptor super-family. Immunol Res. 2011; 51: 5-14.
98. Becker C, Wirtz S, Neurath MF. Stepwise regulation of TH1 responses in autoimmunity: IL-12-related cytokines and their receptors. Inflamm Bowel Dis. 2005; 11: 755-764.
99. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009; 8: 40-52
100. Lehmann D, Spanholtz J, Sturtzel C, Tordoir M, Schlechta B, Groenewegen D, Hofer E. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential. PLoS One. 2014; 9: e87131.
101. Hershey GK. IL-13 receptor and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003; 111: 677-690.
102. Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003; 21: 425-456.
103. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006; 12: 99-106.
104. Shen L, Zhang C, Wang T, Brooks S, Ford RJ, Lin-Lee YC et al. Development of autoimmunity in IL-14alpha-trangenic mice. J Immunol. 2006; 177: 5676-5686
105. Leca N, Laftavi M, Shen L, Matteson K, Ambrus J Jr, Pankewycz O. Regulation of human interleukin 14 transcription in vitro and in vivo after renal transplantation. Transplanta- tion. 2008; 86: 336-341.
106. Shen L, Suresh L, Li H, Zhang C, Kumar V, Pankewycz O et alii. IL-14 alpha, the nexus for primary Sjogren’s disease in mice and humans. Clin Immunol. 2009; 130: 304-312.
107. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012; 33: 35-41.
108. Waldmann TA. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Invest Dermatol. 2013; 16: S28-S30.
109. Richmond J, Tuzova M, Cruikshank W, Center D. Regulation of cellular processes by interleukin-16 in homeostasis and cancer. J Cell Physiol. 2014; 229: 139-147.
110. Cruikshank W, Little F. Interleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol. 2008; 28: 467-483.
111. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D et al. Preferential migration of T regulatory cell induced by IL-16. J Immunol. 2007; 179: 6439-6445
112. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001; 20: 5332-5341.
113. Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol. 2013; 2013: 968549.
114. Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF et alii. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem. 2007; 282: 13447-13455.
115. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011; 34: 149-162.
116. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev. 2010; 21: 413-423.
117. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013; pii: S1044-5323(13)00095-X.
118. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013; 4: 289.
119. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001; 12: 53-72.
120. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol. 2011; 89: 383-392.
121. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homo- logue of human interleukin-10 (IL-10). Genes Immun. 2000; 1: 442-450
122. Logsdon NJ, Deshpande A, Harris BD, Rajashankarand KR, Walter MR. Structural ba- sis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cy- tokines. Proc Natl Acad Sci U S A. 2012; 109: 12704-12709.
123. Kaplan DH. The IL-20 subfamily: bad guys in host defence? Nat Immunol. 2013; 14: 774-775.
124. Gallagher G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth Factor Rev. 2010; 21: 345-352.
125. Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets. 2007; 11: 601-612.